CTLA4 and neoplasm: In a poorly immunogenic melanoma mouse tumor model, combinatorial treatment with granulocyte-macrophage colony stimulating factor (GM-CSF)–transduced tumor cell vaccine and anti-CTLA-4 resulted in tumor rejection that was directly correlated with increased Teff/Treg ratio (31).